Search

Your search keyword '"Kang, Wenqing"' showing total 19 results
Start Over Author "Kang, Wenqing" Search Limiters Full Text
19 results on '"Kang, Wenqing"'

1. Genetic Spectrum of Congenital Anomalies of the Kidney and Urinary Tract in Chinese Newborn Genome Project

Author

Huang, Zhelan, Shen, Qian, Wu, Bingbing, Wang, Huijun, Dong, Xinran, Lu, Yulan, Cheng, Guoqiang, Wang, Laishuan, Lu, Wei, Chen, Liping, Kang, Wenqing, Li, Long, Pan, Xinnian, Wei, Qiufen, Zhuang, Deyi, Chen, Dongmei, Yin, Zhaoqing, Yang, Ling, Ni, Qi, Liu, Renchao, Li, Gang, Zhang, Ping, Qian, Yanyan, Peng, Xiaomin, Wang, Yao, Cao, Yun, Xu, Hong, Hu, Liyuan, Yang, Lin, and Zhou, Wenhao

Published
2023
Full Text
View/download PDF

3. Primary carnitine deficiency: Estimation of prevalence in Chinese population and insights into newborn screening

Author

Ji, Xiaoshan, primary, Ge, Yanzhuang, additional, Ni, Qi, additional, Xu, Suhua, additional, Xiong, Zhongmeng, additional, Yang, Lin, additional, Hu, Liyuan, additional, Cao, Yun, additional, Lu, Yulan, additional, Wei, Qiufen, additional, Kang, Wenqing, additional, Zhuang, Deyi, additional, Zhou, Wenhao, additional, and Dong, Xinran, additional

Published
2023
Full Text
View/download PDF

9. Genetic architecture in neonatal intensive care unit patients with congenital heart defects: a retrospective study from the China Neonatal Genomes Project

Author

Wang, Huijun, primary, Xiao, Feifan, additional, Qian, Yanyan, additional, Wu, Bingbing, additional, Dong, Xinran, additional, Lu, Yulan, additional, Cheng, Guoqiang, additional, Wang, Laishuan, additional, Yan, Kai, additional, Yang, Lin, additional, Chen, Liping, additional, Kang, Wenqing, additional, Li, Long, additional, Pan, Xinnian, additional, Wei, Qiufen, additional, Zhuang, Deyi, additional, Chen, Dongmei, additional, Yin, Zhaoqing, additional, Yang, Ling, additional, Ni, Qi, additional, Liu, Renchao, additional, Li, Gang, additional, Zhang, Ping, additional, Li, Xu, additional, Peng, Xiaomin, additional, Wang, Yao, additional, Chen, Huiyao, additional, Ma, Xiaojing, additional, Liu, Fang, additional, Cao, Yun, additional, Huang, Guoying, additional, and Zhou, Wenhao, additional

Published
2022
Full Text
View/download PDF

11. Neonatal Metabolic Acidosis in the Neonatal Intensive Care Unit: What Are the Genetic Causes?

Author

Ma, Haiyan, primary, Tang, Zezhong, additional, Xiao, Feifan, additional, Li, Long, additional, Li, Yangfang, additional, Tang, Wenyan, additional, Chen, Liping, additional, Kang, Wenqing, additional, Lu, Yulan, additional, Dong, Xinran, additional, Cheng, Guoqiang, additional, Wang, Laishuan, additional, Lu, Wei, additional, Yang, Lin, additional, Ni, Qi, additional, Peng, Xiaomin, additional, Wang, Yao, additional, Cao, Yun, additional, Wu, Bingbing, additional, Zhou, Wenhao, additional, Zhuang, Deyi, additional, Lin, Guang, additional, and Wang, Huijun, additional

Published
2021
Full Text
View/download PDF

12. Genetic architecture in neonatal intensive care unit patients with congenital heart defects: a retrospective study from the China Neonatal Genomes Project

Author

Wang, Huijun, Xiao, Feifan, Qian, Yanyan, Wu, Bingbing, Dong, Xinran, Lu, Yulan, Cheng, Guoqiang, Wang, Laishuan, Yan, Kai, Yang, Lin, Chen, Liping, Kang, Wenqing, Li, Long, Pan, Xinnian, Wei, Qiufen, Zhuang, Deyi, Chen, Dongmei, Yin, Zhaoqing, Yang, Ling, Ni, Qi, Liu, Renchao, Li, Gang, Zhang, Ping, Li, Xu, Peng, Xiaomin, Wang, Yao, Chen, Huiyao, Ma, Xiaojing, Liu, Fang, Cao, Yun, Huang, Guoying, and Zhou, Wenhao

Abstract

BackgroundCongenital heart defects (CHDs) are the most common type of birth defects. The genetic aetiology of CHD is complex and incompletely understood. The overall distribution of genetic causes in patients with CHD from neonatal intensive care units (NICUs) needs to be studied.MethodsCHD cases were extracted from the China Neonatal Genomes Project (2016–2021). Next-generation sequencing results and medical records were retrospectively evaluated to note the frequency of genetic diagnosis and the respective patient outcomes.ResultsIn total, 1795 patients were included. The human phenotype ontology term of atrial septal defect, patent ductus arteriosus and ventricular septal defect account for a large portion of the CHD subtype. Co-occurring extracardiac anomalies were observed in 35.1% of patients. 269 of the cases received genetic diagnoses that could explain the phenotype of CHDs, including 172 copy number variations and 97 pathogenic variants. The detection rate of trio-whole-exome sequencing was higher than clinical exome sequencing (21.8% vs 14.5%, p<0.05). Further follow-up analysis showed the genetic diagnostic rate was higher in the deceased group than in the surviving group (29.0% vs 11.9%, p<0.05).ConclusionThis is the largest cohort study to explore the genetic spectrum of patients with CHD in the NICU in China. Our findings may benefit future work on improving genetic screening and counselling for NICU patients with CHD.

Published
2023
Full Text
View/download PDF

14. Prognostic value of amplitude‐integrated EEG in neonates with high risk of neurological sequelae

Author

Yuan, Xiao, primary, Kang, Wenqing, additional, Song, Juan, additional, Guo, Jing, additional, Guo, Lanlan, additional, Zhang, Ruili, additional, Liu, Shasha, additional, Zhang, Yaodong, additional, Liu, Dapeng, additional, Wang, Yong, additional, Ding, Xue, additional, Dong, Huimin, additional, Chen, Xi, additional, Cheng, Yanchao, additional, Zhang, Xiaoli, additional, Xu, Falin, additional, and Zhu, Changlian, additional

Published
2020
Full Text
View/download PDF

15. Recombinant human erythropoietin improves neurological outcomes in very preterm infants

Author

Song, Juan, Sun, Huiqing, Xu, Falin, Kang, Wenqing, Gao, Liang, Guo, Jiajia, Zhang, Yanhua, Xia, Lei, Wang, Xiaoyang, and Zhu, Changlian

Subjects
Research Articles, Research Article
Abstract

Objective To evaluate the efficacy and safety of repeated low‐dose human recombinant erythropoietin (rhEPO) in the improvement of neurological outcomes in very preterm infants. Methods A total of 800 infants of ≤32‐week gestational age who had been in an intensive care unit within 72 hours after birth were included in the trial between January 2009 and June 2013. Preterm infants were randomly assigned to receive rhEPO (500IU/kg; n = 366) or placebo (n = 377) intravenously within 72 hours after birth and then once every other day for 2 weeks. The primary outcome was death or moderate to severe neurological disability assessed at 18 months of corrected age. Results Death and moderate/severe neurological disability occurred in 91 of 338 very preterm infants (26.9%) in the placebo group and in 43 of 330 very preterm infants (13.0%) in the rhEPO treatment group (relative risk [RR] = 0.40, 95% confidence interval [CI] = 0.27–0.59, p < 0.001) at 18 months of corrected age. The rate of moderate/severe neurological disability in the rhEPO group (22 of 309, 7.1%) was significantly lower compared to the placebo group (57 of 304, 18.8%; RR = 0.32, 95% CI = 0.19–0.55, p < 0.001), and no excess adverse events were observed. Interpretation Repeated low‐dose rhEPO treatment reduced the risk of long‐term neurological disability in very preterm infants with no obvious adverse effects. Ann Neurol 2016;80:24–34

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results